Patent SG-11201908547V-A (SG)
Title: Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
Inventor: STARK SEBASTIAN
IPC: A61K47/69
Filed: 2018-03-22
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT O V SID o Ho Imo En VII IE (10) International Publication Number WO 2018/175788 Al (51) International Patent Classification: A61K 47/61 (2017.01) A61K 47/69 (2017.01) (21) International Application Number: PCT/US2018/023857 (22) International Filing Date: 22 March 2018 (22.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/475,094 22 March 2017 (22.03.2017) US (71) Applicants: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, California 94080 (US). ASCENDIS PHARMA A/S [DK/DK]; Tuborg Boulevard 5, 2900 Hellerup (DK). (72) Inventors: STARK, Sebastian; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, D-69120 Heidelberg (DE). KNAPPE, Thomas; c/o Ascendis Pharman GmbH, Im Neuenheimer Feld 584, D-69120 Heidelberg (DE). RAU, Harald; c/o Ascendis Pharma GmbH, Im Neuen- heimer Feld 584, D-69120 Heidelberg (DE). BISEK, Nico- la; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, D-69120 Heidelberg (DE). LAUFER, Burkhardt; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, D-69120 Heidelberg (DE). WEISBROD, Samuel; c/o As- cendis Pharma GmbH, Im Neuenheimer Feld 584, D-69120 Heidelberg (DE). VOIGT, Tobias; c/o Ascendis Pharma GmbH, Im Neuenheimer Feld 584, D-69120 Heidelberg (DE). FUH, Germaine; 149 Amapola Avenue, Pacifica, California 94044 (US). KOENIG, Patrick; 4116A 17th Street, San Francisco, California 94114 (US). LEE, Ching- wei Vivian; 342 Menhaden Ct., Foster City, California 94404 (US). YADAV, Daniela Bumbaca; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) W O 20 18/ 1757 88 Al (74) Agent: HALL, Robert C. et al.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (54) Title: HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODS (57) : The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.